SCHEMBL16206170

SCHEMBL16206170

COc1ncc(-c2cccc(OCc3c(C)cccc3-n3nnn(C)c3=O)n2)c(OC)n1

nearest known ligand 0.32

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 18/20 0.32
TP53 P04637 4/20 0.32
MDM4 O15151 1/20 0.31
P2RX3 P56373 1/20 0.31
HTR7 P34969 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17614607 0.92 PDE10A (0.33) HTR7
SCHEMBL16206068 0.88 BRD9 (0.36) HTR7
SCHEMBL17614601 0.88 NPC1 (0.32) TP53HTR7
SCHEMBL17614605 0.86 GRM5 (0.32) HTR7
SCHEMBL16206168 0.86 MAOB (0.32) MDM2HTR7
SCHEMBL16206069 0.86 ELANE (0.37) MDM2HTR7
SCHEMBL17614606 0.84 TLR8 (0.36) HTR7
SCHEMBL16205963 0.84 GRM2 (0.37) TP53HTR7
SCHEMBL16206164 0.82 LMNA (0.35) MDM2TP53HTR7
SCHEMBL17614604 0.82 HTR7 (0.31) HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2990404-B1 TETRAZOLINONE COMPOUND AND USE OF SAME SUMITOMO CHEMICAL CO (JP) 2020-05-27 EP disclosed
US-9867372-B2 Tetrazolinone compound and use of same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-01-16 US disclosed
US-20160081339-A1 TETRAZOLINONE COMPOUND AND USE OF SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-03-24 US disclosed
WO-2014175465-A1 TETRAZOLINONE COMPOUND AND USE OF SAME 住友化学株式会社 (JP) 2014-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160081339-A1 TETRAZOLINONE COMPOUND AND USE OF SAME MT-CO1, SOD1, MT-CO2 MDM2 884/4885TP53 4316/4885MDM4 4268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.